NCT06633016招募中2 期
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 230
- 试验地点
- 48
- 主要终点
- Change from Baseline in the 17-item Hamilton Rating Scale for Depression (HAMD-17)
研究概览
简要总结
The goal of this clinical trial is to learn if ABX-002 added to an existing antidepressant treatment will benefit depression symptoms in adults with moderate to severe major depressive disorder who have had an inadequate response to their antidepressant.
This is a double-blind, placebo-controlled, 2-arm, parallel-group, Phase 2 study, randomized 1:1 (ABX-002: placebo).
The study will include the following stages:
- Screening, approximately 35 days
- 42-day Treatment Period
- 2-week post dose Safety Follow-up Period
- 6-month postdose targeted safety follow-up period
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
盲法说明
The study participants, Investigator, and study site staff, Sponsor will be blinded to treatment assignments (ABX-002 or placebo solution).
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Meets the DSM-5 criteria for Major Depressive Disorder, with a current major depressive episode duration of > 6 weeks and ≤ 18 months.
- •A score of ≤ 22 (midrange mild/moderate) on the Hamilton Anxiety Rating Scale.
- •Montgomery-Asberg Depression Rating Scale total score of > 24 [indicating moderate to severe depression] at Screening and at Baseline.
- •Subject is compliantly using a single selective serotonin reuptake inhibitors / serotonin norepinephrine reuptake inhibitor antidepressant for at least 6 weeks for their current episode of depression, with an adequate dose, and with an inadequate response as defined by the Antidepressant Treatment Response Questionnaire. The dosage of the current antidepressant must have been stable for the past 4 weeks, and the dosage and specific antidepressant used should remain the same from Screening through the end of the Follow-up Period.
排除标准
- •Note: History implies lifetime history, unless otherwise specified
- •History of schizophrenia or other psychotic disorder, major depressive disorder with psychotic features or concomitant DSM-5 depressive disorders, bipolar I or II disorder, cyclothymic disorder, delirium, dementia, amnestic disorder, or cognitive disorder.
- •Current diagnosis or active symptoms within the last 2 years of obsessive-compulsive disorder, posttraumatic stress disorder, panic disorder, or eating disorder, according to DSM-5 criteria.
- •Primary diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal, or histrionic personality disorder, according to DSM-5 criteria. Current or history within the last 2 years of self-injurious behavior is exclusionary.
- •Has failed more than 2 single selective serotonin reuptake inhibitors / serotonin norepinephrine reuptake inhibitor antidepressant treatments, including the current serotonin reuptake inhibitors / serotonin norepinephrine reuptake inhibitor, during the current depressive episode, despite an adequate dose (per Antidepressant Treatment Response Questionnaire) and duration (at least 6 weeks).
- •Failure to respond to triiodothyronine or thyroxine augmentation for the treatment of depression.
- •Started new psychotherapy or had a change in the intensity of psychotherapy within 8 weeks before Screening.
- •Is suicidal at Screening or Baseline
- •History or current evidence within previous 3 months before Screening of uncontrolled, clinically significant neurological, gastrointestinal, respiratory, renal, hepatic, immunological, hematological, or other medical disorder, including cancer, that would jeopardize the safe participation of the subject in the study (in the opinion of the Investigator).
- •History of thyroid disease
- •History of multiple endocrine neoplasia syndrome
- •Diagnosis of epilepsy or history of convulsions, including childhood febrile seizure. Use of co-administered drugs that may lower seizure threshold is excluded.
- •Females who are pregnant, intend to become pregnant or are breastfeeding.
- •Antidepressants: Prior use of psychedelics, ketamine, or esketamine, for the treatment of Major Depressive Disorder.
- •Antidepressants: Current use, or use within 4 weeks prior to Screening, of any other augmentation agents for Major Depressive Disorder (e.g. second-generation antipsychotics [SGA], monoamine oxidase inhibitors [MAOI], tricyclic antidepressants [TCA], lithium, or bupropion)
- •Current or prior use of treatment for hypothyroidism including but not limited to synthetic or natural thyroid hormone, triiodothyronine and/or thyroxine.
- •Concomitant use of biotin of any dose and in any preparation 14 days prior to Day 1 until after the last study visit at Week 8 (Day 56).
- •Medications that are strong cytochrome P450 3A4 inhibitors or strong cytochrome P450 3A4 inducers are not allowed.
- •Prescription drug/controlled substance abuse, or illicit substance use within 1 year of Screening or positive urine drug results at Screening or Baseline for an illicit substance.
- •History or presence of cataract on ophthalmic examination (including slit-lamp), glaucoma, inflammatory eye disease or prior ophthalmic surgical procedures or laser surgery in either eye
研究组 & 干预措施
ABX-002 + SSRI/SNRI
Experimental
Patients continue to receive their selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study in addition to ABX-002.
干预措施: ABX-002 (Drug)
Placebo + SSRI/SNRI
Placebo Comparator
Patients continue to receive their selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study in addition to the Placebo.
干预措施: Placebo (Other)
结局指标
主要结局
Change from Baseline in the 17-item Hamilton Rating Scale for Depression (HAMD-17)
时间窗: 6 weeks
The HAMD-17 is a clinician-based assessment of depressive symptoms. Higher scores indicate worse symptoms. A score of 0-9 is generally accepted to be within the normal range (or in clinical remission), while a score of greater than 17 indicates moderate to severe depression symptoms.
次要结局
- Change from Baseline for Clinical Global Impression of Severity (CGI-S)(6 weeks)
- Change from Baseline for Sheehan Disability Scale (SDS)(6 weeks)
- Change from baseline for 6-item Hamilton Rating Scale for Depression (HAMD-6)(6 weeks)
- Change from baseline for 29-item Hamilton Rating Scale for Depression (HAMD-29)(6 weeks)
- Patient Global Impression-Improvement (PGI-I)(6 weeks)
- Assessment of safety and tolerability of ABX-002 compared with placebo using adverse events(6 weeks)
研究者
研究点 (48)
Loading locations...
相似试验
进行中（未招募）
2 期
Phase 2 Estimation Study of Fixed Dose Drugs Combination Type of PolypillAlzheimer DiseaseNCT06597058Noah Pharmaceuticals, Inc.103
已完成
2 期
Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With GoutGoutHyperuricemiaNCT01336686CymaBay Therapeutics, Inc.67
已完成
2 期
Recall Enhancement Through Treatment With Atomoxetine in MS (RETAIN-MS)Memory DisordersMultiple SclerosisNCT03091400Icahn School of Medicine at Mount Sinai11
进行中（未招募）
2 期
Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PDParkinson's DiseaseNCT05819359Bial R&D Investments, S.A.237
已完成
2 期
A Trial of GH001 in Patients With Treatment-resistant DepressionTreatment-resistant DepressionNCT05800860GH Research Ireland Limited81